Bedel Financial Consulting, Inc. Spero Therapeutics, Inc. Transaction History
Bedel Financial Consulting, Inc.
- $645 Million
- Q1 2024
Shares
2 transactions
Others Institutions Holding SPRO
# of Institutions
53Shares Held
15.4MCall Options Held
19.6KPut Options Held
0-
Anson Funds Management LP Dallas, TX3.75MShares$5.18 Million1.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.65MShares$2.28 Million0.0% of portfolio
-
Atlas Venture Associates Ix, LLC Boston, MA1.35MShares$1.87 Million14.54% of portfolio
-
Adar1 Capital Management, LLC Austin, TX927KShares$1.28 Million0.36% of portfolio
-
Alphabet Inc. Mountain View, CA890KShares$1.23 Million0.07% of portfolio
About Spero Therapeutics, Inc.
- Ticker SPRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,067,500
- Market Cap $48.4M
- Description
- Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...